A recent audit of Dr. Reddy's active pharmaceutical ingredient manufacturing plant at Hyderabad, India by the US Food and Drug Administration has led the agency to issue a ‘Form 483’ with five observations. The company has responded saying they “will address the observations comprehensively within the stipulated timeline.”
For Dr Reddy’s, the good manufacturing practice compliance issues come at a time when they have recently become eligible for...





